Method for predicting prognosis of solid cancer patient
A comprehensive panel-based study of 410 genes in ctDNA from plasma accurately detects driver mutations, improving prognosis and treatment prediction in solid tumors by correlating mutation numbers with patient outcomes.
Patent Information
- Application Number
- JP2024071280
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-04-25
- Filing Date
- 2024-04-25
- Publication Date
- 2024-11-07
AI Technical Summary
Current methods for detecting cell-free DNA (ctDNA) in peripheral blood have insufficient sensitivity and cannot accurately identify cancer-specific mutations, particularly in solid tumors like pancreatic cancer, making it difficult to predict prognosis and treatment effectiveness.
Conduct a comprehensive panel-based study targeting 410 genes using cell-free DNA extracted from plasma to detect driver mutations, correlating the number of mutations with patient prognosis and treatment effectiveness.
The method allows for high-sensitivity detection of driver mutations, enabling accurate prediction of patient prognosis and treatment effectiveness in solid cancers, facilitating personalized medicine.
Smart Images

Figure 2024157553000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for predicting the prognosis of a solid cancer patient, a method for stratifying a solid cancer patient, a method for predicting the effectiveness of a treatment for a solid cancer patient, and a kit for use in these methods. [Background technology]
[0002] Pancreatic cancer (PC) has become the third leading cause of cancer-related deaths in recent years. It is predicted to become the second leading cause of cancer-related deaths within the next decade. Although radical resection is essential to achieve cure, only 15-20% of all pancreatic cancer patients have no evidence of locally advanced and metastatic disease. Although there have been great advances in perioperative chemotherapy and / or radiotherapy regimens, surgical techniques, and perioperative management, pancreatic cancer remains a disease with an extremely poor prognosis. In clinical settings, cancer antigen 19-9 (CA19-9) is the most useful molecular biomarker, but few molecules have been reported as promising potential biomarkers for pancreatic cancer. In recent years, the need for biomarkers to identify sensitivity to treatment and predict prognosis has been emphasized in the development of personalized treatments targeting genetic alterations in pancreatic cancer. In addition, similar biomarkers are still needed not only for pancreatic cancer but also for other solid cancers in general.
[0003] It is known that cell-free nucleic acids are present in peripheral blood. Continuous molecular monitoring of tumors using non-invasive blood sampling, so-called "liquid biopsy (LB)", may be an ideal option for cancer patients and develop "personalized" cancer management. Cell-free circulating tumor DNA (ctDNA) is a promising tool for early tumor detection and It is expected to be a biomarker that will improve monitoring of tumor dynamics (Non-Patent Document 1).
[0004] For example, among the major driver genes of pancreatic cancer, KRAS mutations have been detected in many pancreatic cancer cases, most of which are located in hotspots (G12D, G12V, G12R, or Q61H). Therefore, the main methods for quantifying low-abundance point mutations in ctDNA have been digital droplet polymerase chain reaction (ddPCR) or targeted sequencing of KRAS mutations. However, conventional ctDNA assays have insufficient detection sensitivity and are mixed with mutations occurring in normal cells (e.g., somatic mutations associated with clonal hematopoiesis), making it impossible to identify cancer-specific mutations (Non-Patent Document 2). It has also been pointed out that it is difficult to identify genomic changes specific to early cancers, including resectable pancreatic cancer (Non-Patent Document 3). [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Nat Med. 2008;14(9):985-90. [Non-Patent Document 2] Molecular oncology. 2020;14(8):1719-30. [Non-Patent Document 3] Gastroenterology. 2019;156(1):108-18.e4. Summary of the Invention [Problem to be solved by the invention]
[0006] Thus, there is no consensus on the optimal method for detecting ctDNA, and no examples of panel-based comprehensive research on somatic mutations in ctDNA in solid cancers such as resectable pancreatic cancer have been reported. Therefore, the present invention aims to detect gene mutations in ctDNA derived from patients with solid cancers such as pancreatic cancer with high sensitivity, find useful biomarkers for solid cancers, and use them to predict the prognosis of patients and the effectiveness of treatments. [Means for solving the problem]
[0007] The present inventors conducted a panel-based comprehensive study of 410 genes using cell-free DNA extracted from preoperative plasma in patients with solid cancers such as pancreatic cancer, and performed variant calling and paired analysis (tumor and normal). In addition, the effect of the number of driver mutations detected in cell-free DNA on prognosis was examined. As a result, it was found for the first time that the number of driver mutations detected in cell-free DNA is a prognostic biomarker for solid cancers such as pancreatic cancer and a predictor of early recurrence. Based on these findings, the present invention has been completed.
[0008] That is, the present invention is specified by the following items. [1] A method for predicting the prognosis of a patient with solid cancer, comprising: determining the number of driver mutations in the gene of interest in the ctDNA contained in a blood sample from the patient; and Correlating the number of driver mutations with a prognosis for the patient. Including, In the association, when the number of driver mutations is 1 or more, it is associated with a higher possibility of poor prognosis compared to when the number of driver mutations is 0, and when the number of driver mutations is 2 or more, it is associated with an even higher possibility of poor prognosis compared to when the number of driver mutations is 1 or less. The method. [2] The method according to [1] above, wherein the target genes include one or more selected from the group consisting of TP53, KRAS, KIT, APC, EGFR, SMAD4, CSDE1, NRAS, ALK, BRAF, CDKN2A, CDKN2A-AS1, GNAS, IDH2, KEAP1, MAP2K1, MTOR, BRCA2, EGFR-AS1, ERBB4, and PIK3CA. [3] Driver mutations were TP53 G245S, TP53 R158C, TP53 R175H, and TP53 R213. *, TP53 R273C, TP53 R306 * , TP53 Y220 * , TP53 I255F, TP53 N239D, TP53 P278A, TP53 Q192YfsTer14, TP53 R273H, TP53 S241F, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12C, KRAS G13D, KRAS G13R, KIT G592W, KIT K558N, KIT L589R, APC E1306 * , APC R876 * , APC S1436fs, EGFR G719C, EGFR S492R, EGFR E709G, EGFR E746_A750del, EGFR G719A, EGFR L858R, EGFR T790M, EGFR,EGFR-AS1 S768I, SMAD4 R361C, SMAD4 R361H, NRAS G13V, NRAS Q61K, ALK G1123D, BRAF G469R, BRAF V600E, BRCA2 P1519fs, CDKN2A R80 * The method according to [1] or [2] above, comprising one or more selected from the group consisting of GNAS R844C, GNAS R201C, GNAS R201H, IDH2 R140Q, KEAP1 G423V, MAP2K1 P124L, MAP2K1 F129L, MTOR C1483Y, ERBB4 R847H, PIK3CA D352Y, PIK3CA H1047R, and PIK3CA Q546K. [4] The method according to any one of [1] to [3] above, wherein the driver mutation is a somatic mutation. [5] The method according to any one of [1] to [4] above, wherein the solid cancer is pancreatic cancer, lung cancer, colon cancer, or thyroid cancer. [6] The method according to [5] above, wherein the pancreatic cancer is resectable pancreatic cancer. [7] The method according to any one of [1] to [6] above, wherein the blood sample is collected from the patient before resection of a solid cancer. [8] The method according to any one of [1] to [7] above, wherein the blood sample is plasma. [9] The method according to any one of [1] to [8] above, wherein the prognosis is a prognosis after surgical resection of a solid cancer.
[10] The method according to any one of [1] to [9] above, wherein the poor prognosis is one or more selected from the group consisting of worsening overall survival, worsening cancer recurrence-free survival, and cancer metastasis.
[11] The method according to
[10] above, wherein the worsening of recurrence-free survival time is early recurrence within 6 months after resection.
[12] The method according to
[10] above, wherein the cancer metastasis is liver metastasis.
[13] 1. A method for stratifying a patient with a solid tumor, comprising: determining the number of driver mutations in the gene of interest in the ctDNA contained in a blood sample from the patient; and stratifying the patient into any of groups including a group in which the number of driver mutations is 0, a group in which the number of driver mutations is 1, and a group in which the number of driver mutations is 2 or more; The method comprising:
[14] The method according to
[13] above, for predicting the efficacy of a treatment for a solid cancer patient.
[15] 1. A method for predicting the efficacy of a treatment for a solid cancer patient, comprising: stratifying the patient by the method according to
[13] above; and assessing actionable mutations in a gene of interest in ctDNA contained in a blood sample from the patient; The method comprising:
[16] Evaluating actionable mutations in the target genes is Confirming the presence or absence of actionable mutations in the target genes; If the actionable mutation is present, confirm the details and evidence level of the actionable mutation; and Correlating the presence or absence, content, or evidence level of the actionable mutation with the efficacy of a treatment; The method according to claim 15, comprising:
[17] The method according to any one of
[14] to
[16] above, wherein the therapy is drug therapy or postoperative adjuvant therapy.
[18] A kit for use in the method according to any one of [1] to
[17] above, comprising a reagent for use in confirming genetic changes, including the number of driver mutations in a target gene or the presence or absence of actionable mutations. Effect of the Invention
[0009] According to the present invention, by detecting driver mutations in ctDNA contained in a blood sample of a solid cancer patient, samples can be collected easily and non-invasively, and driver mutations can be detected with high sensitivity, compared to when the detection target is tumor tissue. Furthermore, according to the present invention, by using the number of driver mutations as a biomarker, the prognosis of a patient can be predicted with high accuracy, and further, the effectiveness of a treatment can be predicted. Therefore, it can contribute to the development of stratified medicine and personalized medicine. [Brief description of the drawings]
[0010] [Figure 1(a)] FIG. 1 shows the flow of patient enrollment and sample collection. [Figure 1(b)] FIG. 1 shows a method for evaluating the drivability of somatic mutations. [Figure 1(c)] FIG. 1 shows a method for evaluating the actionability of somatic mutations. [Diagram 2] (a) A graph showing the frequency of tier 1 and tier 2 mutations identified in LB from pancreatic cancer patients. (b) A graph showing the frequency of tier 1 and tier 2 mutations identified in tumor tissue analysis from pancreatic cancer patients. [Diagram 3]Figure 1 shows the identification of driver mutations in LB and tumor tissue analysis of pancreatic cancer patients, comparing the specific mutations identified in plasma ctDNA and tumor tissue of each patient. [Figure 4] (a) A diagram showing the results of an analysis of overall survival (OS) and recurrence-free survival (RFS) in pancreatic cancer patients according to ctDNA positivity (b). [Diagram 5] (a) Quantification of tier 1 mutations detected in ctDNA of pancreatic cancer patients. (b) Stratification of OS according to the number of driver mutations in pancreatic cancer patients. (c) Stratification of RFS according to the number of driver mutations in pancreatic cancer patients. [Figure 6] (a) Quantification of tier 1 mutations detected in ctDNA from lung cancer, colorectal cancer, and thyroid cancer patients. (b) Stratification of OS according to the number of driver mutations in lung cancer, colorectal cancer, and thyroid cancer patients. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0011] (Method of the Invention) The present invention relates to a first method, a second method, and a third method which will be described in detail below (these may be collectively referred to as the "methods of the present invention").
[0012] (First method: A method for predicting the prognosis of patients with solid cancer) The first method of the present invention is a method for predicting the prognosis of a patient with solid cancer. The first method of the present invention includes the following (Step A) and (Step B). (Step A) Confirming the number of driver mutations in the gene of interest in the ctDNA contained in a blood sample derived from the patient. (Step B) Correlating the number of driver mutations with the prognosis of the patient.
[0013] The above-mentioned (Step B) also includes the following (Step B-1) and (Step B-2). (Step B-1) In the association, when the number of driver mutations is 1 or more, it is associated with a higher possibility of poor prognosis compared with when the number of driver mutations is 0. (Step B-2) In the association, when the number of driver mutations is two or more, it is associated with a higher possibility of poor prognosis compared to when the number of driver mutations is one or less.
[0014] The first method of the present invention includes any method for predicting the prognosis of a solid cancer patient. For example, it may include a "method for collecting data for predicting the prognosis of a solid cancer patient," a "method for creating data for predicting the prognosis of a solid cancer patient," a "method for providing data for predicting the prognosis of a solid cancer patient," and a "method for predicting the prognosis of a solid cancer patient." Note that "data" includes "information" and "indices," etc. Furthermore, "prediction" includes "evaluation" and "judgment," etc.
[0015] (Second method: stratifying patients with solid tumors) The second method of the present invention is a method for stratifying solid cancer patients. The second method of the present invention includes the following (Step A) and (Step C). (Step A) Confirming the number of driver mutations in the gene of interest in the ctDNA contained in a blood sample derived from the patient. (Step C) stratifying the patient into any group including a group in which the number of driver mutations is 0, a group in which the number is 1, and a group in which the number is 2 or more.
[0016] The second method of the present invention may include, for example, a "method for stratifying the prognosis of solid cancer patients (stratifying solid cancer patients into expected prognoses)" and a "method for stratifying solid cancer patients into treatment cohorts." In addition, the "method for stratifying solid cancer patients" of the present invention can also be used for each group stratified by the number of driver mutations, for example, to "predict the effectiveness of a treatment for solid cancer patients," "to assist in the selection of a treatment for solid cancer patients," or "to prevent cancer recurrence." However, as a method for predicting the effectiveness of a treatment for solid cancer patients with even higher accuracy, the following third method can also be used.
[0017] (Third method: A method for predicting the efficacy of treatment for patients with solid tumors) The third method of the present invention is a method for predicting the effectiveness of a treatment for a solid cancer patient. The third method of the present invention includes the following (step A), (step C), and (step D): (step A) confirming the number of driver mutations in a target gene in ctDNA contained in a blood sample derived from the patient. (Step C) stratifying the patient into any group including a group in which the number of driver mutations is 0, a group in which the number is 1, and a group in which the number is 2 or more. (Step D) Evaluating actionable mutations in the target gene in the ctDNA contained in the blood sample derived from the patient.
[0018] The third method of the present invention includes any method for predicting the effectiveness of a therapy for a solid cancer patient. For example, it may include "a method for collecting data for predicting the effectiveness of a therapy for a solid cancer patient", "a method for creating data for predicting the effectiveness of a therapy for a solid cancer patient", "a method for providing data for predicting the effectiveness of a therapy for a solid cancer patient", "a method for predicting the effectiveness of a specific drug (medicine) for a solid cancer patient", "a method for selecting a drug (medicine) for a solid cancer patient", and "a method for predicting the effectiveness of a therapy for a solid cancer patient". Note that "data" includes "information" and "indices", etc. Also, "prediction" includes "evaluation" and "determination", etc. Also, the "drug (medicine)" may be a molecular targeted drug or an immune checkpoint inhibitor, etc., for example, a molecular targeted drug or an immune checkpoint inhibitor that targets a molecule or immune checkpoint associated with the actionable mutation identified in step D.
[0019] The data obtained by the method of the present invention may be provided to medical professionals such as doctors. The data obtained by the method of the present invention can be used to determine a treatment plan based on the genomic information of each patient. However, the method of the present invention does not include a diagnostic action by a doctor. In addition, the method of the present invention can be combined with other methods to perform comprehensive prediction, evaluation, or judgment.
[0020] (prognosis) In the present invention, "prognosis" means an outlook for medical progress, and may mean, for example, progress after resection of solid cancer. Examples of "prognosis" include overall survival (OS, the period from the start of a certain treatment to death), recurrence-free survival (RFS, the period from the start of a certain treatment to recurrence for a patient who has been cured by surgery or the like), survival rate after a certain period, recurrence-free rate after a certain period, and the presence or absence of metastasis. Examples of the certain period include 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years, etc. Recurrence includes local recurrence, peritoneal recurrence, and distant organ recurrence. Local recurrence also includes recurrence in regional lymph nodes. Examples of metastasis include lymph node metastasis, peritoneal metastasis, liver metastasis, lung metastasis, etc., and include metastasis to a single site and metastasis to multiple sites.
[0021] (Predicting prognosis) In the present invention, "predicting prognosis" means judging or evaluating the possibility that "prognosis" is good or bad. Examples of "poor prognosis" include worsening overall survival (shorter overall survival), worsening cancer recurrence-free survival (shorter recurrence-free survival), worsening survival rate after a certain period (lower survival rate after a certain period), worsening recurrence-free rate after a certain period (lower recurrence-free rate after a certain period), and / or occurrence of cancer metastasis. Worsening recurrence-free survival includes early recurrence within 6 months after resection. In addition, whether there is a difference in the length of survival is generally statistically compared and defined by the log-rank test, but is not limited thereto. In predicting whether an individual patient will have a long or short survival time, a long survival time may mean a longer than the average survival time predicted from the patient's pathology, and a short survival time may mean a shorter than the average survival time predicted from the patient's pathology.
[0022] (Solid tumors) In the present invention, the "solid cancer" is not particularly limited, but examples thereof include pancreatic cancer, lung cancer, colon cancer, thyroid cancer, stomach cancer, liver cancer, brain tumor, esophageal cancer, duodenal cancer, small intestine cancer, skin cancer, breast cancer, prostate cancer, bladder cancer, vaginal cancer, cervical cancer, uterine cancer, kidney cancer, spleen cancer, tracheal cancer, bronchial cancer, head and neck cancer, gallbladder cancer, bile duct cancer, testicular cancer, sarcoma, soft tissue tumor, bone cancer, and ovarian cancer, among which pancreatic cancer, lung cancer, colon cancer, and thyroid cancer are preferable, and pancreatic cancer is more preferable.
[0023] (Pancreatic cancer) In the present invention, pancreatic cancer may include pancreatic cancer of all resectability classifications or pancreatic cancer of all disease stages. Pancreatic cancer is classified into resectable pancreatic cancer, borderline resectable pancreatic cancer, and unresectable pancreatic cancer according to resectability. As long as it is necessary to predict the prognosis of a patient, the pancreatic cancer targeted in the present invention is not particularly limited, but resectable pancreatic cancer is particularly preferred. In this case, by predicting the prognosis with high accuracy using the method of the present invention, it is possible to effectively assist in considering surgical adaptation and selecting a treatment method. Note that the stage of pancreatic cancer is classified into stages 0 to IV as it progresses from early stage, and pancreatic cancer in stages 0 to II, which is relatively early, generally corresponds to resectable pancreatic cancer.
[0024] (Solid tumor patients) In the present invention, the solid cancer patient may be a mammal, preferably a primate, and most preferably a human. In the present invention, the sex, age, species (race), etc. of the solid cancer patient are not particularly limited, and examples thereof include Caucasians, Blacks, and Asians (e.g., Japanese).
[0025] (Blood sample) Although blood samples can be collected from patients as needed, it is preferable to collect blood samples from patients before resection of solid cancer such as pancreatic cancer. In such cases, highly accurate prognosis prediction using the method of the present invention can effectively assist in the consideration of surgical suitability and selection of treatment methods for solid cancer such as resectable pancreatic cancer.
[0026] (Process A) The method of the present invention involves identifying the number of driver mutations in a gene of interest in ctDNA contained in a patient-derived blood sample (Step A). Here, the specific method of (Step A) is not particularly limited as long as the object can be achieved, but may include, for example, some or all of the following steps (Step A-1) to (Step A-5). (Step A-1) Separating plasma from a blood sample taken from a patient. (Step A-2) Extracting cell-free DNA from plasma. (Step A-3) Detecting somatic mutations in the target gene in ctDNA in cell-free DNA. (Step A-4) Classifying the detected somatic mutations as driver mutations or not. (Step A-5) Counting the number of somatic mutations classified as driver mutations.
[0027] (plasma) In the present invention, plasma may be separated from a blood sample derived from a patient. By separating plasma from a blood sample and using it, blood cells are removed, so that the subsequent steps can be carried out efficiently. The separation method is not particularly limited, and examples thereof include a method using centrifugation or a filter.
[0028] (Cell-free DNA) In the present invention, the method for extracting cell-free DNA from a blood sample or plasma is not particularly limited and can be performed by a known method. For example, a commercially available kit such as the QIAamp circulating nucleic acid kit (manufactured by Qiagen) can be used. "Circulating tumor DNA (ctDNA)" refers to DNA floating in the blood, and includes DNA derived from the death of normal blood cells, as well as circulating tumor DNA (ctDNA) derived from the genomic DNA of cancer cells. "ctDNA" is the genomic DNA of cancer cells that leaks into the blood when cancer cells are destroyed by the immune system, undergo cell death (apoptosis), or when circulating tumor cells that have leaked into the blood are destroyed in the blood due to some influence. If a driver mutation is detected in cell-free DNA, there is a possibility, although the probability is low, that it is DNA derived from the death of normal blood cells, that is, a driver mutation in DNA derived from the germline. However, if the driver mutation has a low mutant allele frequency of less than 30%, it is likely to be a driver mutation in DNA derived from tumor cells (ctDNA), and if the driver mutation has a high mutant allele frequency of 30% or more, it is likely to be a driver mutation in DNA derived from normal cells (germline).
[0029] (Target gene) In the present invention, the method for detecting driver mutations in the "target gene" is not particularly limited, and known methods can be used, but when a next-generation sequencer is used in particular, driver mutations in many genes can be detected efficiently. In addition, when many genes are targeted, comprehensive analysis may be performed on a panel basis, in which case driver mutations can be detected more efficiently.
[0030] In the present invention, the number of "target genes" is not particularly limited, but it is preferable to target a large number of genes. A large number can be, for example, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 20 or more, 30 or more, 40 or more, 50 or more, 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 150 or more, 200 or more, 250 or more, 300 or more, 350 or more, 400 or more, 410 (pieces), etc. When a large number of genes are targeted, it is possible to realize more accurate prediction of prognosis, etc., compared to targeting one gene or a small number of genes, such as KRAS gene, as in many conventional techniques.
[0031] In the present invention, the specific type of "target gene" is not particularly limited, and may include, for example, a gene with a relatively high possibility of detecting a driver mutation, or may include a gene with a relatively high possibility of detecting a driver mutation and a gene with a relatively low possibility of detecting a driver mutation. By analyzing a large number of genes including them, the possibility of detecting a driver mutation with higher sensitivity is increased. The "target gene" may include, for example, one or more selected from the 410 cancer-related genes shown in Table 1 below, or may not include them. In addition, a part or all of the 410 genes shown in Table 1 (i.e., one or more selected from the 410 genes shown in Table 1) may be combined with one or more genes not shown in Table 1 to be the target.
[0032] [Table 1] TIFF2024157553000003.tif224157TIFF2024157553000004.tif224152TIFF2024157553000005.tif89167
[0033] In the present invention, the type of "target gene" is not particularly limited, but it is preferably a gene highly related to solid cancer, for example, TP53; KRAS; KIT; APC; EGFR; SMAD4; CSDE1; NRAS; ALK; BRAF; CDKN2A; CDKN2A-AS1; GNAS; IDH2; KEAP1; MAP2K1; MTOR; BRCA2; EGFR-AS1; ERBB4; and PIK3CA, and preferably includes one or more selected from the group consisting of, for example, any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 (number) selected from the above group. By including a large number of genes highly related to these solid cancers as targets, more accurate prognosis prediction can be achieved. The type and number of "target genes" may be selected depending on the type of target solid cancer, etc.
[0034] (Driver Mutation) In the present invention, the term "driver mutation" refers to a gene mutation that is a direct cause of the onset or progression of cancer. Somatic mutations and germline mutations can be distinguished by performing a matched pair analysis of tumor tissue and normal tissue (e.g., peripheral blood). In addition, clonal hematopoiesis of indeterminate potential (CHIP) can also be excluded. In the present invention, the detected somatic mutations can be classified by sequential comparison with annotation databases (CGI, DoCM, OncoKB, IARC-TP53, ClinVar) (Figure 1b). A mutation classified as tier 1 (registered in the database as a pathogenic / carcinogenic mutation) can be defined as a "driver mutation". A mutation classified as tier 2 (registered in the database as having the possibility of being a pathogenic / carcinogenic mutation) can be defined as a "mutation that may be a driver mutation". In the present invention, "mutation" includes single base substitution and insertion / deletion.
[0035] In the present invention, the specific type of "driver mutation" is not particularly limited, and may be, for example, a mutation defined as a driver mutation by the above-mentioned method. However, specific examples include one or more of the mutations shown in Table 2 below.
[0036] [Table 2] TIFF2024157553000007.tif194170 SEQ ID NO:2: GGAATTAAGAGAAGC SEQ ID NO: 3: ACCTACTCTATTGGGTTTTCATACAGCTAGCGGGAAAAAAGTTAAAATTGCAAAGGAATCTTTGGACAA SEQ ID NO: 4: GATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTGAGCACTCTTTCCCTACACGACGCTCTTCCGATCT
[0037] Therefore, in the present invention, the "driver mutation" is TP53 G245S, TP53 R158C, TP53 R175H, TP53 R213 * , TP53 R273C, TP53 R306 * , TP53 Y220 * , TP53 I255F, TP53 N239D, TP53 P278A, TP53 Q192YfsTer14, TP53 R273H, TP53 S241F, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12C, KRAS G13D, KRAS G13R, KIT G592W, KIT K558N, KIT L589R, APC E1306 * , APC R876 * , APC S1436fs, EGFR G719C, EGFR S492R, EGFR E709G, EGFR E746_A750del, EGFR G719A, EGFR L858R, EGFR T790M, EGFR,EGFR-AS1 S768I, SMAD4 R361C, SMAD4 R361H, NRAS G13V, NRAS Q61K, ALK G1123D, BRAF G469R, BRAF V600E, BRCA2 P1519fs, CDKN2A R80 * , GNAS R844C, GNAS R201C, GNAS R201H, IDH2 R140Q, KEAP1 G423V, MAP2K1 P124L, MAP2K1 F129L, MTOR C1483Y, ERBB4 R847H, PIK3CA D352Y, PIK3CA H1047R, and PIK3CA Q546K, or may not include one or more selected from the group consisting of GNAS R844C, GNAS R201C, GNAS R201H, IDH2 R140Q, KEAP1 G423V, MAP2K1 P124L, MAP2K1 F129L, MTOR C1483Y, ERBB4 R847H, PIK3CA D352Y, PIK3CA H1047R, and PIK3CA Q546K.
[0038] Here, for example, "TP53 G245S" refers to a mutation in which the 245th G (glycine) of TP53 is replaced with S (serine). *" represents a mutation in which the 213th R (arginine) of TP53 is replaced with a stop codon. For example, "APC S1436fs" represents a frameshift mutation at the 1436th S (serine) of APC. For example, "EGFR E746_A750del" represents a mutation in which the 750th A (alanine) is deleted from the 746th E (glutamic acid) of EGFR. For example, "TP53 Q192YfsTer14" represents a mutation in which a mutation occurs below the 192nd Q (glutamine) of TP53 as a result of a frameshift mutation, creating a new reading frame starting with Y (tyrosine), and the 14th reading frame counting from there becomes a stop codon. For example, "EGFR, EGFR-AS1 S768I" indicates that there is a mutation in which the 768th S (serine) is replaced with I (isoleucine) at the same position in both EGFR and its antisense encoded EGFR-AS1. The one-letter abbreviations of amino acids correspond as follows: A: alanine, C: cysteine, D: aspartic acid, E: glutamic acid, F: phenylalanine, G: glycine, H: histidine, I: isoleucine, K: lysine, L: leucine, M: methionine, N: asparagine, P: proline, Q: glutamine, R: arginine, S: serine, T: threonine, V: valine, W: tryptophan, Y: tyrosine.
[0039] In the present invention, the "driver mutation" does not necessarily have to be accompanied by a change in amino acid. For example, it may be a mutation outside the region encoding amino acids, such as a single-base mutation in a downstream region outside the region encoding amino acids of CSDE1 or CDKN2A-AS1. It may also be a mutation accompanied by the generation of a stop codon or a deletion.
[0040] In the present invention, "checking the number of driver mutations" means counting the number of somatic mutations classified as driver mutations. The number of driver mutations may be, for example, 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 (pieces), or more. In the present invention, the number of driver mutations may be classified as either "0", "1", or "2 or more", and "2 or more" may be further classified as "2", "3", "3 or more", "4", "4 or more", "5", and / or "5 or more". In addition, "1 or less" means "0" or "1", "1 or more" means "1" or "2 or more", and "2 or more" means "2" or "3 or more".
[0041] (Process B) The first method of the present invention includes correlating the number of driver mutations with the prognosis of a patient (Step B). Here, the "correlation" in (Step B) is performed as follows: (Step B-1) and (Step B-2).
[0042] (Process B-1) In the present invention, the number of driver mutations of 1 or more is associated with a higher possibility of poor prognosis compared with the case where the number of driver mutations is zero.
[0043] (Process B-2) In the present invention, a case where the number of driver mutations is 2 or more is associated with a higher possibility of poor prognosis compared to a case where the number of driver mutations is 1 or less. Here, "higher" means that the possibility of association in (Step B-2) is higher than the possibility of association in (Step B-1) above.
[0044] Moreover, the first method of the present invention may further include the following (Step B-3), (Step B-4) and / or (Step B-5).
[0045] (Process B-3) In the present invention, a case where the number of driver mutations is 3 or more is associated with a higher possibility of poor prognosis compared to a case where the number of driver mutations is 2 or less. Here, "higher" means that the possibility of association in (Step B-3) is higher than the possibility of association in (Step B-1) and / or (Step B-2) above.
[0046] (Process B-4) In the present invention, a case where the number of driver mutations is 4 or more is associated with a higher possibility of poor prognosis compared to a case where the number of driver mutations is 3 or less. Here, "higher" means that the possibility of association in (Step B-4) is higher than the possibility of association in (Step B-1), (Step B-2) and / or (Step B-3) above.
[0047] (Process B-5) In the present invention, a number of driver mutations of 5 or more is associated with a higher possibility of poor prognosis compared to a number of driver mutations of 4 or less. Here, "higher" means that the possibility of association in (Step B-5) is higher than the possibility of association in (Step B-1), (Step B-2), (Step B-3) and / or (Step B-4) above.
[0048] (Association) In the present invention, information on the possibility of poor prognosis indicated by the association may be provided to medical personnel such as doctors. However, the association itself is not a diagnostic act by a doctor and may be performed by anyone.
[0049] (Process C) The second method of the present invention includes stratifying patients into any group including a group in which the number of driver mutations is 0, a group in which the number is 1, and a group in which the number is 2 or more (Step C).
[0050] (stratification) In the present invention, "stratifying patients" includes, for example, "stratifying the prognosis of solid cancer patients (stratifying solid cancer patients into expected prognosis)" and "stratifying solid cancer patients into treatment cohorts." Stratification can, for example, assist in the selection of a more appropriate treatment for each group, or predict the effectiveness of a treatment for each group. In the present invention, patients may be stratified into either "group with 0 driver mutations," "group with 1," or "group with 2 or more driver mutations," but the "group with 2 or more driver mutations" may be further classified into "group with 2 driver mutations," "group with 3 driver mutations," "group with 3 or more driver mutations," "group with 4 driver mutations," "group with 4 or more driver mutations," "group with 5 driver mutations," and / or "group with 5 or more driver mutations." Patients may also be further stratified into "group with 6 driver mutations," "group with 7 driver mutations," "group with 8 driver mutations," "group with 9 driver mutations," "group with 10 driver mutations," or "group with more driver mutations."
[0051] (Treatment method) As described above, the second method of the present invention can also be used to predict the effectiveness of a treatment for a solid cancer patient. In the present invention, the treatment includes surgery, drug therapy (chemotherapy), postoperative adjuvant therapy, radiation therapy, chemoradiotherapy, adjuvant chemotherapy, stent therapy, bypass therapy, supportive / palliative therapy, etc. Furthermore, the drug includes a molecular targeted drug or an immune checkpoint inhibitor, etc.
[0052] (Process D) A third method of the present invention includes evaluating actionable mutations in a gene of interest in ctDNA contained in a patient-derived blood sample (step D). Here, the specific method of (Step D) is not particularly limited as long as the object can be achieved, but may include, for example, some or all of the following steps (Step D-1) to (Step D-3). (Step D-1) Confirming the presence or absence of actionable mutations in the target gene. (Step D-2) If the actionable mutation is present, confirm the content and evidence level of the actionable mutation. (Step D-3) Correlating the presence or absence, content, or evidence level of the actionable mutation with the effectiveness of the treatment.
[0053] (Actionable mutations / Druggable mutations) In the present invention, the detected somatic mutations may be evaluated from the viewpoint of "driver" as well as "actionable" and / or "druggable". In the present invention, "actionable mutation" means a gene mutation that is a target of a molecular targeted drug in various stages of development. In the present invention, actionable mutations can be classified into five levels, A to E, based on the evidence levels proposed by the Center for Cancer Genomics and Advanced Therapeutics (C-CAT). Actionable mutations can be evaluated in two steps. In step 1, the drug approval status can be classified into four categories according to the description in the annotation database. Then, in step 2, the evidence level can be assigned according to the matching of the drug approval status and cancer type between the database and the query. The highest evidence level is level A (this change in evidence level is defined as "druggable mutation"), followed by B, C, D, and E (Figure 1c). "Druggable mutation" refers to a genetic mutation that is the target of a molecular targeted drug or immune checkpoint inhibitor that can be clinically applied to the same cancer type. The presence or absence, content, and / or evidence level of actionable mutations and / or druggable mutations can be useful information for predicting the effectiveness of treatments, including the selection of therapeutic drugs. Treatments include, in particular, drug therapy or postoperative adjuvant therapy.
[0054] (kit) The present invention also relates to a kit for use in the first method, the second method, or the third method of the present invention (which may be referred to as the "first kit," the "second kit," or the "third kit," respectively; these may also be collectively referred to as the "kit of the present invention."). The kit of the present invention may be provided as a kit for gene panel testing, particularly a kit for cancer gene panel testing.
[0055] The kit of the present invention includes reagents necessary for each purpose. Specifically, it includes a reagent for use in confirming the number of driver mutations or genetic changes including the presence or absence of actionable mutations in a gene of interest. The kit of the present invention includes a reagent for use in confirming the number of driver mutations or the presence or absence of actionable mutations in a gene of interest, but may further include a reagent for use in detecting, confirming, or evaluating one or more other genetic mutations or genetic changes. In the present invention, "gene mutation" means single base substitution and insertion deletion, and "genetic change" means all of "gene mutation", "structural abnormality" (fusion gene), and "expression abnormality" (amplification of cancer gene and deletion of cancer suppressor gene). In addition, the kit of the present invention may further include other things in addition to the reagent. The other things may include, but are not limited to, for example, a container, a tool, an instruction manual for the method or procedure of use, an instruction manual for carrying out the method of the present invention, other attached documents, a recording medium, an analysis program, a database on genetic mutations and genetic abnormalities, and the like. In addition, one or more of the reagents and other things may be included. Furthermore, the kit of the present invention may be used in combination with a genetic analyzer such as a next-generation sequencer, or an information processing device such as a computer.
[0056] (reagent) In the present invention, examples of the "reagent" include primers, probes, enzymes, buffers, stabilizers, carriers, solvents, cleaning solutions, other PCR reagents, other sequencing reagents, other hybridization reagents, etc. The primers or probes may be labeled with enzymes, fluorescent substances, luminescent substances, color-developing substances, radioactive substances, other chemical substances, etc. The primers or probes may be combined with one or more other primers or probes and included in the kit as a primer set or a probe set. A panel including multiple probes may also be included in the kit. In the present invention, the reagent may include, for example, one or more primers or probes targeting one or more genes selected from those shown in Table 1, and preferably one or more primers or probes targeting one or more genes selected from those shown in Table 2, and particularly preferably one or more primers or probes designed to detect one or more driver mutations selected from those shown in Table 2. The base sequence of the primer or probe can be appropriately designed by a standard method based on the base sequence information of the target gene, and can be designed as a primer or probe having a base sequence complementary to all or part of the base sequence of a particularly target genome range in the target gene, or a base sequence highly identical thereto. The target genome range can be, for example, a base sequence consisting of several to several thousand bases including a mutation position or a mutation region (exon) of a hotspot of the target gene, and can be, for example, one or more selected from the genome ranges shown in Table 3.
[0057] (First Kit) The first kit of the present invention is a kit whose use is specified as “for use in a method for predicting the prognosis of a solid cancer patient.” The first kit of the present invention includes a reagent for use in confirming the number of driver mutations in a gene of interest.
[0058] (Second Kit) The second kit of the present invention is a kit whose use is specified as "for use in a method for stratifying solid cancer patients." The second kit of the present invention includes a reagent for use in confirming the number of driver mutations in a gene of interest.
[0059] (Third Kit) The third kit of the present invention is a kit whose use is specified as "for use in a method for predicting the efficacy of a therapy for a solid cancer patient." The third kit of the present invention includes a reagent for use in confirming the number of driver mutations in a target gene and a reagent for use in confirming the presence or absence of an actionable mutation in the target gene.
[0060] The present invention will be described in more detail below using examples, although the technical scope of the present invention is not limited to these examples. EXAMPLES
[0061] [Example 1] Study targeting pancreatic cancer patients 1. Materials and Methods 1-1. Patients and samples This study was conducted with written consent from all participating patients and with the approval of the Institutional Review Board of Shizuoka Cancer Center. Patients who underwent cancer removal surgery at Shizuoka Cancer Center Hospital and could provide a sufficient amount of fresh cancer tissue were included. A total of 103 cases of pancreatic cancer were analyzed between January 2014 and March 2019. All tumor tissues were pathologically diagnosed as pancreatic cancer. In addition, peripheral blood was collected as a control for Whole Exome Sequencing (WES) to identify genomic alterations in the patients' somatic and germline cells, and Comprehensive Cancer Panel (CCP) sequencing was performed on the tumor tissues. Plasma samples were collected for liquid biopsy (LB). Of these, 33 patients with resectable pancreatic cancer for whom plasma samples were available were enrolled in this study (Figure 1a). Resectability was defined according to the classification of the National Comprehensive Cancer Network (NCCN) guidelines.
[0062] 1-2. Next-generation sequencing of tumor tissue Detailed experimental protocols and analysis procedures for sequence data have been reported previously (Biomedical research (Tokyo, Japan). 2016;37(6):359-66.; Biomedical research (Tokyo, Japan). 2016;37(6):367-79.; Cancer science. 2020;111(2):687-99.). Briefly, fresh surgical specimens were evaluated by a pathologist, and tumor samples weighing more than 20 mg were collected. In addition, peripheral blood was collected as a control for WES and CCP sequencing of solid tumor samples to identify genomic alterations in the patients' somatic and germline cells. DNA was extracted from tissues and peripheral blood samples using the QIAampDNA Blood Mini Kit (Qiagen) according to the manufacturer's instructions.
[0063] WES libraries were constructed using the Ion AmpliSeq Exome RDY Kit (Thermo Fisher Scientific), and CCP libraries were constructed using the Ion AmpliSeq library Kit 2.0 (Thermo Fisher Scientific), following the manufacturer's recommended protocol. The constructed libraries were quantified by quantitative PCR, and DNA sequences were determined using a semiconductor DNA sequencer (Ion Torrent Proton Sequencer, Thermo Fisher Scientific) following the manufacturer's instructions. The average read depth (number of sequence reads per base in the analyzed region) for WES and CCP was 130 and 1169, respectively.
[0064] The raw binary data obtained by the sequencer were converted into sequence reads that were mapped to the reference human genome (UCSC hg19) using Torrent Suite software (ver. 4.4, Thermo Fisher Scientific). At this time, the sequence data of the tumor samples and blood samples were analyzed separately, and the mapping results were saved as BAM files. The two BAM files were uploaded to the Ion Reporter system and simultaneously analyzed using the AmpliSeq exometumor-normal pair workflow (ver. 4.4; Thermo Fisher Scientific) with a CustomHotspot file that specified somatic and pathogenic mutations registered in COSMIC and ClinVar, respectively.
[0065] 1-3.Next-generation sequencing of LB Twenty milliliters of blood samples were collected in EDTA tubes and centrifuged twice (1900 × g, 10 min, 4 °C) within 2 hours of extraction to separate plasma. Plasma was then aliquoted and stored at -80 °C. cfDNA was extracted from plasma samples using a QIAamp circulating nucleic acid kit (Qiagen) and quantified using a Qubit 3.0 Fluorometer and high sensitivity assay kits (Thermo Fisher Scientific). The quality of the cfDNA samples was analyzed on an Agilent 4200 TapeStation (Agilent Technologies). Samples were considered acceptable for further next-generation sequencing studies if they showed a peak of approximately 165 bp, had no evidence of significant genomic DNA contamination, and at least 30 ng of sample was available.
[0066] The target capture panel was specifically designed to target 410 genes shown in Table 3, by selecting the entire coding regions of 40 druggable or potentially actionable genes and hotspot regions of 370 genes, as reported in the JCGA study (Cancer science. 2020; 111(2): 687-99.).
[0067] [Table 3] TIFF2024157553000009.tif224165TIFF2024157553000010.tif224165TIFF2024157553000011.tif224165 TIFF2024157553000012.tif224165TIFF2024157553000013.tif224165TIFF2024157553000014.tif224165 TIFF2024157553000015.tif224165TIFF2024157553000016.tif224165TIFF2024157553000017.tif224165 TIFF2024157553000018.tif224165TIFF2024157553000019.tif224165TIFF2024157553000020.tif115165
[0068] The panel was designed using the Agilent SureDesign Web application (v. 7.5; Agilent Technologies) to cover coding exons and untranslated regions. The panel encompasses up to 13,400 probes divided into two probe groups, with 2-fold density and balanced boosting, covering a target region of 38.627 Mbp.
[0069] Libraries were prepared using a custom gene panel according to the SureSelectXT HS2 DNA System with Pre-Capture Pooling protocol (Agilent Technologies). Libraries of cfDNA were prepared starting from 25 ng of DNA bypassing the fragmentation step as described in a published application note. Libraries were sequenced on a NovaSeq 6000 (Illumina) platform using the NovaSeq 6000 S4 Reagent Kit v1.5 (300 cycles) (Illumina). Variant calling and paired analysis (tumor vs. normal) were performed using the DRAGEN Bio-IT Platform (v. 4.2; Illumina).
[0070] 1-4. Evaluation of driver and actionable mutations Somatic mutations were classified by sequentially comparing the list of mutations with the annotation database (Fig. 1b). Mutations classified as tier 1 were defined as driver mutations, and mutations classified as tier 2 were defined as possible driver mutations (Cancerscience. 2020;111(2):687-99.). Actionable changes were classified into five levels, A to E, based on the evidence levels proposed by the Center for Cancer Genomics and Advanced Therapeutics (C-CAT). Actionable mutations were evaluated in two steps. In step 1, the drug approval status was classified into four categories according to the description in the annotation database. Then, in step 2, the evidence level was assigned according to the matching of the drug approval status and cancer type between the database and the query. The highest evidence level was level A (mutations with this evidence level were defined as druggable mutations), followed by B, C, D, and E (Fig. 1c).
[0071] 1-5. Treatment policy and surgical results During the study period, no neoadjuvant therapy was administered for resectable pancreatic cancer, so no patients in this cohort received neoadjuvant therapy. Surgical resection was performed as previously reported (World journal of surgery. 2012;36(12):2888-94.). Adjuvant chemotherapy was usually selected with S-1 (The Lancet. 2016;388(10041):248-57.).
[0072] 1-6. Definitions of surgical and pathological outcomes Resected specimens were examined by a pathologist and graded according to the American Joint Committee on Cancer / Union for International Cancer Control (AJCC / UICC) staging system, 8th edition (AJCC Cancer Staging Manual. Springer International Publishing. 2017.). Final surgical margins were considered positive if tumor cells were detected microscopically in any of the resection margins. Recurrence after resection was classified as local recurrence, peritoneal recurrence, or distant organ recurrence according to the site of the lesion at the time of first recurrence. Local recurrence also included recurrence in regional lymph nodes. Cases with metastases at multiple sites at the time of first recurrence were counted twice.
[0073] 1-7.Statistical analysis Continuous variables were expressed as median and IQR (interquartile range) and compared using the Mann-Whitney U test. Survival rates were calculated by the Kaplan-Meier method, and the log-rank test was used to evaluate the statistical significance of differences. All statistical analyses were performed using the JMP software package (version 14.0 for Mac; SAS Institute). A P value of <0.05 was considered to indicate statistical significance.
[0074] 2.Results 2-1. Clinicopathological characteristics This cohort consisted of plasma and paired tumor samples from 33 patients with resectable pancreatic cancer treated at Shizuoka Cancer Center Hospital between January 2014 and March 2019. Clinicopathological characteristics are summarized in Table 6. The histological type was adenocarcinoma in all cases, and adenosquamous carcinoma and other special types were not included. The most common pathological stage was stage IIB (42.4%), followed by stage III (27.2%). No patients received neoadjuvant therapy. The median follow-up period was 38.0 months. The 3- and 5-year overall survival (OS) rates were 54.4% and 32.3%, respectively.
[0075] 2-2. Driver and actionable mutations in LB of pancreatic cancer Of the 33 cases, a total of 39 tier 1 mutations (Table 4) and a total of 93 tier 2 mutations (Table 5) were detected in LBs from 30 cases (90.9%) (Figure 2a). Tier 1 mutations were detected in 21 cases (63.6%), and tier 2 mutations were detected in 29 cases (87.9%). Genes with tier 1 mutations, ranked in order of frequency, were as follows: TP53 (27.3%), KRAS (15.2%), KIT (12.1%), APC (9.1%), EGFR (6.1%), SMAD4 (6.1%), CDKN2A (3.0%), CDKN2A-AS1 (3.0%), GNAS (3.0%), IDH2 (3.0%), KEAP1 (3.0%), MAP2K1 (3.0%), and MTOR (3.0%).
[0076] Genes with tier 2 mutations at a frequency of 5% or higher were ranked in descending order of frequency as follows: TP53 (42.4%), EGFR (9.1%), CBL (9.1%), JAK1 (9.1%), KIT (6.1%), CDKN1B (6.1%), CTNNB1 (6.1%), EGFR-AS1 (6.1%), ERBB2 (6.1%), ERRFI1 (6.1%), KMT2D (6.1%), MSH2 (6.1%), NF2 (6.1%), NOTCH1 (6.1%), PIK3CA (6.1%), PPP2R1A (6.1%), RUNX1 (6.1%), and SMARCA4 (6.1%).
[0077] [Table 4] TIFF2024157553000022.tif75170
[0078] [Table 5] TIFF2024157553000024.tif219170TIFF2024157553000025.tif183170Sequence number 1: CCCAGGGCTCCTCGTTCCATCTCCGCTTCTCGCCTCCACTGCTGCTGGGCTGGGGGCTCCCCACACGGATGCTGACTTCTTGGAAGGCTGAAGCCTCTGGGCCCTGGGAGCCAGCACCAGGACCAAGGACAGCCGACTCACCAGGGATCAGAAGTTGTGATTCCTCTGAGCCTAGATCAGGCCTGCAGGCTTTGGGGGCCCCCAGAAAATCTGGGACCTCACTGTGACATCGCTGTAACCAGCCAGGATCTAGGGAGCCCAGCCGCTGGCTCAGGGATGCCTGCAGATGCTGGAGCCGGCCTGGCCTTGGCTGGGGCTCAGGGAGCTGTGGAGGCTCATCACTGACTTTTTCTGCAAAGGAGGGGACAGGCCCTGTACCTGGGGGCTTTGGGGTGGATGCCTTAGATGAGGCTCTTCCTAGAGGCCACGGTCTGCGGCCCAGGGCTGGTCCGGCCTGGGAGGGGAACAACAGAACAGCAGGAGGAACTCAGGCCCCTGAGCTACTGTAGACTCTAAAACCTACCTGAGTCCCCACGCTCAATTGTAGAGCAGGCTAATTAGCACAAGGCTGGACTAGAAAGGGAGTCAAGGGCGAAGGCCCCGAGAAGCTCCCTGAAGACTCGTGCCCTGGTTGGCACAGGGGCCCGTGCCTGTCTGTGTGGAAAAAATGACAAGAGGGCGACCCGGACCGGAAGCAGCTGTGGACCTAGCGTGGACTCACTGCCTGCCCACTCCTCACCTGCAGGGTGCCTTTCAGATTGGCCTTGAGCCGCTGCCCGTAGTCCGGCACCGAGCCCTGGCGGCTCCGCCCTGGCGTAGACTGTGGACTCTTGGTCGCAGCCCGATTCAGATGGGGCCCCCAGCAGCGGGGCTCTGGC
[0079] In 33 cases, no level A or level B actionable mutations were identified. Twenty-six level C mutations were identified in 18 cases (54.5%), and eight level D mutations were identified in eight cases (24.2%). Genes with level C or D mutations, ranked in order of frequency, were as follows: KIT (24.2%), KRAS (24.2%), PDGFRA (21.2%), TP53 (15.2%), EGFR (9.1%), ALK (3.0%), IDH2 (3.0%), and NRAS (3.0%).
[0080] 2-3. Driver mutations in pancreatic cancer tumor tissue analysis Fresh surgical specimens were used for WES and CCP deep sequencing (Fig. 2b). WES identified KRAS (48.5%) and TP53 (6.1%) as tier 1 mutations, and TP53 (21.2%), CDKN2A (6.1%), ARID3A (3.0%), DNMT3A (3.0%), KMT2D (3.0%), PALB2 (3.0%), and SF381 (3.0%) as tier 2 mutations.
[0081] In CCP, only KRAS (66.7%) and TP53 (6.1%) were identified as tier 1 mutations, whereas TP53 (33.3%), KMT2D (9.1%), CDKN2A (6.1%), DNMT3A (3.0%), HNF1A (3.0%), MITF (3.0%), MUTYH (3.0%), PALB2 (3.0%), RECQL4 (3.0%), and SF381 (3.0%) were identified as tier 2 mutations.
[0082] As a result of integrated analysis of WES and CCP using tumor tissue, a total of 24 tier 1 mutations and 29 tier 2 mutations were detected in 26 cases (78.8%) of tumor tissue specimens by WES, and a total of 25 tier 1 mutations were detected in 22 cases (66.7%) of CCP, and a total of 30 tier 2 mutations were detected in 19 cases (57.6%) of CCP.
[0083] 2-4. Identification of driver mutations in LB and tumor tissue analysis To compare the efficacy of LB with that of tumor tissue analysis, LB and the corresponding tumor tissues were analyzed by WES and / or CCP (Figure 3). The concordance rate of tier 1 mutation detection between LB and tumor tissue analysis was 42.4% (14 / 33). Furthermore, multiple tier 1 mutations were identified in tumor tissues of 2 of 33 cases (6.1%). This is in contrast to the fact that analysis of ctDNA revealed multiple tier 1 mutations in 9 of 33 cases (27.3%).
[0084] KRAS mutations were detected as tier 1 mutations in 5 cases (15.2%) in ctDNA and 22 cases (66.7%) in tumor tissue. The concordance rate of KRAS mutation status between LB and tumor tissue analysis was 30.3% (10 / 34). TP53 mutations were detected as tier 1 mutations in 9 cases (27.3%) and 2 cases (6.1%) in ctDNA and tumor tissue, respectively. The concordance rate of TP53 mutation status between LB and tumor tissue analysis was 72.7% (24 / 34). Although less frequent, LB was able to detect many other driver mutations not detected by tumor tissue analysis, including ALK, APC, BRAF, EGFR, GNAS, IDH2, KEAP1, KIT, MAP2K1, MTOR, and NRAS.
[0085] 2-5. Clinicopathological factors according to identification of driver mutations in LB and tumor tissue analysis in patients with resectable pancreatic cancer LB positivity and tumor tissue analysis positivity were defined as whether or not a tier 1 mutation was identified. Of the 33 patients, 21 (63.6%) were classified as ctDNA positive and 22 (66.7%) as tumor tissue positive. Clinicopathological factors according to the definitions are shown in Table 6. The ctDNA positive group had significantly higher CA19-9 values than the ctDNA negative group (P = 0.017). The tumor tissue positive group was more likely to have negative resection margins than the tumor tissue negative group (P = 0.031).
[0086] [Table 6]
[0087] 2-6. Impact of ctDNA positivity on treatment outcomes in patients with resectable pancreatic cancer In the ctDNA-positive group, overall survival (OS) was significantly worse than in the ctDNA-negative group (median, 25.6 months vs. not reached, P = 0.009, Fig. 4a). Recurrence-free survival (RFS) was also significantly worse in the ctDNA-positive group than in the ctDNA-negative group (median, 10.9 months vs. not reached, P = 0.001, Fig. 4b). Cox proportional hazards analysis of OS (Table 7) revealed that ctDNA positivity was an independent prognostic factor (P = 0.019), and lymph node metastasis (P = 0.004) was also an independent predictor of reduced survival. To investigate the impact of ctDNA positivity on the pattern of recurrence, the correlation between ctDNA positivity and the site of first recurrence and the time after resection was evaluated (Table 8). The ctDNA-positive group had a higher rate of liver metastasis than the ctDNA-negative group (P = 0.007). In the ctDNA-negative group, all patients who experienced a recurrence (100%, 4 / 4) had a local recurrence, and no recurrence in distant organs (lungs, liver, etc.) was observed. Early recurrence within 6 months after surgery was significantly more frequent in the ctDNA-positive group (P = 0.013).
[0088] [Table 7]
[0089] [Table 8]
[0090] 2-7. Usefulness of assessing the number of driver mutations in LBs of pancreatic cancer patients We quantified the tier 1 mutations detected by LB (Fig. 5a). At least one tier 1 mutation was identified in 21 of 33 cases (63.6%) by LB. Furthermore, multiple tier 1 mutations were identified in ctDNA in 9 of 33 cases (27.3%), with one patient having up to five mutations. Patient OS was stratified by the number of mutations, and the OS tended to worsen as the number of mutations increased (number of driver mutations, 0 vs. 1, P = 0.054; 1 vs. ≥ 2, P = 0.147, Fig. 5b). Specifically, when the number of tier 1 mutations was 0, the 3-year OS of patients was 75.0%, when the number of tier 1 mutations was 1, the 3-year OS of patients was 58.3%, and when the number of tier 1 mutations was ≥ 2, the 3-year OS of patients was 22.2%. RFS was also stratified by the number of mutations, and the RFS tended to worsen as the number of mutations increased (number of driver mutations, 0 vs. 1, P = 0.004; 1 vs. ≥ 2, P = 0.189, Fig. 5c). Specifically, the 2-year RFS of patients with 0 tier 1 mutations was 66.7%, the 2-year RFS of patients with 1 tier 1 mutation was 33.3%, and the 2-year RFS of patients with ≥ 2 tier 1 mutations was 22.2%. Early recurrence within 6 months after surgery was significantly more frequent in the group with 2 or more tier 1 mutations (5 / 9, 55.6%) than in the group with one tier 1 mutation (1 / 12, 8.3%) (P = 0.018).
[0091] 3. Discussion In Example 1, comprehensive genetic analysis of ctDNA was performed using preoperative plasma samples from resectable pancreatic cancer. As a result, somatic driver mutations were detected in 65% of cases. It was found that cases in which driver mutations were positive by LB had significantly earlier and more frequent distant metastasis recurrence and poor prognosis. The detected driver mutations included not only KRAS, but also TP53, CDKN2A, and SMAD4, which are recognized as major driver genes in pancreatic carcinogenesis. In addition, other driver mutations such as ALK, APC, BRAF, EGFR, GNAS, IDH2, KEAP1, KIT, MAP2K1, MTOR, and NRAS were found, although they were detected at low frequencies, and these are included in actionable mutations. In particular, in pancreatic cancer, it is relatively difficult to diagnose gene mutations using tumor tissue due to the abundant fibrous stroma in the tumor, the heterogeneity of tumor tissue, and anatomical features (an official journal of the American Association for Cancer Research.2017;23(20):6094-100.). The characteristics of LB are recognized as useful for overcoming these difficulties, and are expected to be particularly useful for pancreatic cancer. The prognosis of patients with resectable pancreatic cancer was stratified according to the results of comprehensive genomic profiling of ctDNA. In addition to being useful for predicting the prognosis of pancreatic cancer patients, comprehensive genomic profiling of ctDNA can be a fundamental resource for developing personalized medicine for pancreatic cancer based on LB findings.
[0092] In addition, we also investigated the effect of the number of driver mutations detected in LB samples on prognosis. As a result, it was revealed that the more driver mutations detected by LB, the worse the prognosis, and that in cases in which multiple driver mutations were confirmed in ctDNA, early recurrence increased significantly. We report for the first time that the number of driver mutations detected by LB is a prognostic biomarker for pancreatic cancer and a predictor of early recurrence. It was suggested that prognosis can be predicted more accurately by investigating mutations in not only KRAS but also other genes and monitoring the number of driver mutations throughout the treatment process.
[0093] [Example 2] Study targeting patients with solid cancer other than pancreatic cancer 1. Materials and Methods 1-1. Patients and samples A total of 31 patients, including 14 lung cancer patients, 16 colon cancer patients, and 1 thyroid cancer patient, were subjected to plasma samples taken from the patients before resection of each cancer for LB and evaluation of driver mutations was performed in the same manner as in Example 1. However, the target capture panel was specially designed for the 70 genes shown in Table 9.
[0094] [Table 9] TIFF2024157553000030.tif225152TIFF2024157553000031.tif46159
[0095] 2.Results 2-1. Driver mutations in LB Of the 31 cases, a total of 41 tier 1 mutations (Table 10) were detected in LB from 22 cases (71.0%).
[0096] [Table 10] TIFF2024157553000033.tif105170 SEQ ID NO:2: GGAATTAAGAGAAGC SEQ ID NO: 3: ACCTACTCTATTGGGTTTTCATACAGCTAGCGGGAAAAAAGTTAAAATTGCAAAGGAATCTTTGGACAA SEQ ID NO: 4: GATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTGAGCACTCTTTCCCTACACGACGCTCTTCCGATCT
[0097] 2-2. Usefulness of assessing the number of driver mutations in LB We quantified the tier 1 mutations detected by LB (Table 11, Figure 6a). At least one tier 1 mutation was identified in 22 of 31 cases (71.0%) by LB. In addition, multiple tier 1 mutations were identified in ctDNA in 11 of 31 cases (35.5%), with one patient having up to six mutations. The number of mutations stratified the OS after resection of each cancer in patients, and the OS tended to worsen as the number of mutations increased (number of driver mutations, 0 vs. 1, P = 0.0404, Figure 6b). Specifically, when the number of tier 1 mutations was 0, the 3-year OS of patients was 55.6%, when the number of tier 1 mutations was 1, the 3-year OS of patients was 27.3%, and when the number of tier 1 mutations was ≥ 2, the 3-year OS of patients was 9.1%.
[0098] [Table 11]
[0099] 3. Discussion In Example 2, the effect of the number of driver mutations detected in LB samples on prognosis was examined for patients with lung cancer, colon cancer, and thyroid cancer. As a result, it was revealed that the more driver mutations detected in LB, the worse the prognosis, as in Example 1 for pancreatic cancer patients. These results suggest that the number of driver mutations detected by LB is a useful prognostic biomarker not only for pancreatic cancer but also for solid cancers in general. [Industrial Applicability]
[0100] The present invention is expected to be applicable to cancer gene panel testing or kits therefor, and therefore can be effectively used particularly in the pharmaceutical field.
Claims
1. A method for predicting the prognosis of a patient with solid cancer, comprising: determining the number of driver mutations in the gene of interest in the ctDNA contained in a blood sample from the patient; and Correlating the number of driver mutations with a prognosis for the patient. Including, In the association, when the number of driver mutations is 1 or more, it is associated with a higher possibility of poor prognosis compared to when the number of driver mutations is 0, and when the number of driver mutations is 2 or more, it is associated with an even higher possibility of poor prognosis compared to when the number of driver mutations is 1 or less. The method.
2. The method of claim 1, wherein the target gene comprises one or more selected from the group consisting of TP53, KRAS, KIT, APC, EGFR, SMAD4, CSDE1, NRAS, ALK, BRAF, CDKN2A, CDKN2A-AS1, GNAS, IDH2, KEAP1, MAP2K1, MTOR, BRCA2, EGFR-AS1, ERBB4, and PIK3CA.
3. Driver mutations were TP53 G245S, TP53 R158C, TP53 R175H, and TP53 R213. * , TP53 R273C, TP53 R306 * , TP53 Y220 * , TP53 I255F, TP53 N239D, TP53 P278A, TP53 Q192YfsTer14, TP53 R273H, TP53 S241F, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12C, KRAS G13D, KRAS G13R, KIT G592W, KIT K558N, KIT L589R, APC E1306 * , APC R876 * , APC S1436fs, EGFR G719C, EGFR S492R, EGFR E709G, EGFR E746_A750del, EGFR G719A, EGFR L858R, EGFR T790M, EGFR, EGFR-AS1 S768I, SMAD4 R361C, SMAD4 R361H, NRAS G13V, NRAS Q61K, ALK G1123D, BRAF G469R, BRAF V600E, BRCA2 P1519fs, CDKN2A R80 * 3. The method of claim 1 or 2, comprising one or more selected from the group consisting of GNAS R844C, GNAS R201C, GNAS R201H, IDH2 R140Q, KEAP1 G423V, MAP2K1 P124L, MAP2K1 F129L, MTOR C1483Y, ERBB4 R847H, PIK3CA D352Y, PIK3CA H1047R, and PIK3CA Q546K.
4. The method of claim 1 or 2, wherein the driver mutation is a somatic mutation.
5. The method according to claim 1 or 2, wherein the solid cancer is pancreatic cancer, lung cancer, colon cancer, or thyroid cancer.
6. The method of claim 5 , wherein the pancreatic cancer is resectable pancreatic cancer.
7. The method according to claim 1 or 2, wherein the blood sample is taken from the patient prior to surgery for resection of the solid cancer.
8. The method according to claim 1 or 2, wherein the blood sample is plasma.
9. The method according to claim 1 or 2, wherein the prognosis is a prognosis after surgical resection of a solid cancer.
10. The method according to claim 1 or 2, wherein the poor prognosis is one or more selected from the group consisting of poor overall survival, poor cancer recurrence-free survival, and cancer metastasis.
11. The method according to claim 10, wherein the deterioration of recurrence-free survival is early recurrence within 6 months after resection.
12. The method according to claim 10, wherein the cancer metastasis is liver metastasis.
13. 1. A method for stratifying a patient with a solid tumor, comprising: determining the number of driver mutations in the gene of interest in the ctDNA contained in a blood sample from the patient; and stratifying the patient into any of groups including a group in which the number of driver mutations is 0, a group in which the number of driver mutations is 1, and a group in which the number of driver mutations is 2 or more; The method comprising:
14. The method according to claim 13 for predicting the efficacy of a treatment for a solid cancer patient.
15. 1. A method for predicting the efficacy of a treatment for a solid cancer patient, comprising: stratifying the patient according to the method of claim 13; and assessing actionable mutations in a gene of interest in ctDNA contained in a blood sample from the patient; The method comprising:
16. Evaluating actionable mutations in the target genes is Confirming the presence or absence of actionable mutations in the target genes; If the actionable mutation is present, confirm the details and evidence level of the actionable mutation; and Correlating the presence or absence, content, or evidence level of the actionable mutation with the efficacy of a treatment; 16. The method of claim 15, comprising:
17. The method according to any one of claims 14 to 16, wherein the therapy is drug therapy or postoperative adjuvant therapy.
18. A kit for use in the method according to any one of claims 1 or 13 to 16, comprising a reagent for use in confirming genetic alterations, including the number of driver mutations or the presence or absence of actionable mutations in a gene of interest.
